The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
A. P. Yu
Employment or Leadership Position - Analysis Group
M. Namjoshi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Xie
Employment or Leadership Position - Analysis Group
K. Parikh
Employment or Leadership Position - Analysis Group
E. Q. Wu
Employment or Leadership Position - Analysis Group
A. Guo
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
K. W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis